Assessing the Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Differential Diagnosis Between Spinal Schwannomas and Meningiomas

Hiroya Ono 1, Gentarou Kumagai 1, Kanichiro Wada 1, Atsushi Ono 2, Toru Asari 1, Masahiro Aoki 3, Yasuyuki Ishibashi 1

1. Department of Orthopedic Surgery, Hirono University Graduate School of Medicine, Hirono, JPN
2. Department of Orthopedics, Hirono Memorial Hospital, Hirono, JPN
3. Department of Radiation and Oncology, Hirono University Graduate School of Medicine, Hirono, JPN

Corresponding author: Gentarou Kumagai, gen722@hirosaki-u.ac.jp

Abstract

Objective
The advantage of 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) for the differential diagnosis of schwannoma and meningioma remains unclear. The purpose of this study was to compare the maximum standardized uptake value (SUVmax) with computed tomography (CT) and magnetic resonance imaging (MRI) findings and assess its utility in the differential diagnosis of schwannomas and meningiomas.

Methods
This study included 42 patients who underwent surgery and had pathological diagnoses of schwannomas (S group) or meningiomas (M group). Multivariate logistic regression analyses were conducted using meningioma prevalence as the dependent variable, and confounders were selected from those with p-values <0.05, including calcification, dural tail sign, tumor volume, and SUVmax at each spinal level as independent variables.

Results
The SUVmax of the spinal canal type at the level of the cervical vertebrae was significantly higher in the M group (4.6 ± 0.8) than in the S group (2.7 ± 1.4; P = 0.017). Multivariate logistic regression analysis showed that the dural tail sign was significantly associated with differential diagnosis between the S and M groups (odds ratio [OR], 0.851; 95% confidence interval [CI], 0.704-1.031, p<0.001).

Conclusions
The dural tail sign on MRI, but not the SUVmax of FDG-PET, was the most useful for the differential diagnosis between schwannomas and meningiomas.

Introduction
Spinal schwannomas and meningiomas are intradural extramedullary tumors that are mostly benign. These tumors represent 25%-40% of all spinal tumors [1-3]. Computed tomography (CT) and magnetic resonance imaging (MRI) are widely used for the differential diagnosis. The presence of calcification or the dural tail sign (thickening and enhancement of the peripheral dura adherent to the tumor on contrast-enhanced MRI, resulting in the appearance of a tail) are characteristic findings in meningiomas [4-7]. However, reports suggest that certain cases are difficult to distinguish based on these findings, especially the spinal canal type [7]. Since it is necessary to select appropriate surgical methods according to accurate preoperative distinction [2,8,9], CT and MRI alone may not be sufficient.

Positron emission tomography (PET) is a nuclear medical imaging method that uses radioactive isotopes [10]. It has gained popularity as a diagnostic imaging technique for detecting abnormalities in metabolism at the cellular molecular level [11]. Currently, the most commonly used PET tracer in clinical practice is 18F-fluorodeoxyglucose (FDG), which is recognized as a useful modality for the diagnosis of malignant tumors [12]. Although PET has good quantitative capability and is useful for detecting lesions, its ability for anatomical evaluation is limited [10]. However, in recent years, PET/CT fusion devices, which combine CT images, have become popular, and are useful for anatomical evaluation [13].
In the field of orthopedics, FDG-PET is widely used for the qualitative assessment of metastatic cancer and inflammatory diseases [14-17]. However, its utility in spinal cord tumors has not yet been demonstrated. In addition, there have been no reports demonstrating that the maximum standardized uptake value (SUVmax) on FDG-PET may aid in distinguishing between schwannomas and meningiomas at each spinal level, and between benign and malignant tumors.

The purpose of this study was to compare the SUVmax with CT and MRI findings and assess its utility in the differential diagnosis of schwannomas and meningiomas.

Materials And Methods

Subjects
Among the 89 patients who underwent FDG-PET/CT for spinal cord tumors at our institution between October 2009 and February 2020, 42 patients who underwent surgery and were pathologically diagnosed with schwannomas (S group) or meningiomas (M group) were included in this study. Patients with multiple lesions and lack of data were excluded (Figure 1). Informed consent was obtained from all participants in this study. This study was approved by the IRB of the authors’ affiliated institutions (the ethics committee of Hirosaki University Graduate School of Medicine, 2019-1038).

![Flow diagram of the study.](image)

Among the 89 patients who underwent FDG-PET/CT for spinal cord tumors at our institution between October 2009 and February 2020, 42 patients who underwent surgery and were pathologically diagnosed with schwannomas (S group) or meningiomas (M group) were included in this study. There were 28 and 14 cases in the S and M groups, respectively. The S group included 9 men and 19 women, and the M group included 2 men and 12 women.

FDG-PET: 18F-fluorodeoxyglucose-positron emission tomography; CT: computed tomography.

Radiographic assessment (CT, MRI, and FDG-PET/CT)
All patients underwent CT (General Electric Healthcare, Waukesha, WI, USA) (WL: 300, WW: 1200) and contrast-enhanced MRI (Signa HDxt 1.5T, 3.0T, General Electric Healthcare, Waukesha, WI) (TE: 1 ms, TR: 5 ms) of the entire spine, and FDG-PET/CT (General Electric Healthcare, Discovery STE, Tokyo, Japan) before surgery (Figures 2, 3). At our hospital, the CT and MR images were interpreted by orthopedic surgeons, and the FDG-PET/CT images were interpreted by radiologists. The prevalence of calcification in the tumors was evaluated using CT. The tumor level, type (spinal canal type or dumbbell type), location (ventral type or dorsal type), and prevalence of the dural tail sign were evaluated using contrast-enhanced MRI. The tumor volumes in contrast-enhanced MRI were evaluated using MRI reconstruction software (Zed-Edit, Lexi, Tokyo, Japan) (Figure 4) [18]. Two examiners (OK, a spine surgeon with 17 years of experience; and HO, an orthopedic surgeon with 7 years of experience) measured the tumor volume. The intra-rater reliability of this measurement (intraclass coefficient correlation [ICC (1, 1)]) by OK was 0.960 (95% confidence interval [CI]: 0.873-0.988; P < 0.001), and HO was 0.956 (95% CI: 0.872-0.976; p < 0.001). Moreover, the inter-rater reliability (ICC (2, 1)) by OK and HO was 0.959 (95% CI: 0.849-0.990; P < 0.001). The SUVmax was evaluated using FDG-PET/CT (SUV = specific radioactivity [Bq/g] / injected dose [Bq] / body weight [kg]).
FIGURE 2: Representative CT and MRI findings of schwannomas and meningiomas.

(A–D) Schwannoma (spinal canal type). (E–H) Meningioma (spinal canal type). (A, B, E, F) CT images. (C, D, G, H) Contrast-enhanced MRI findings.

CT: computed tomography; MRI: magnetic resonance imaging.

FIGURE 3: Representative PET/CT images of schwannomas and meningiomas.

(A, B) Schwannoma (spinal canal type). (C, D) Schwannoma (dumbbell type). (E, F) Meningioma (spinal canal type).

PET: positron emission tomography; CT: computed tomography.
Statistical analysis

The data input and statistical calculations were performed using the SPSS ver.24.0 (SPSS Inc., Chicago, IL, USA) software package. The Mann-Whitney U test was used to test for differences in mean age, body mass index (BMI), duration of disease, tumor volume, and SUVmax between the S and M groups. SUVmax was compared between the two groups at the cervical, thoracic, and lumbar levels for each type of tumor. The chi-squared test was used to test for differences in sex, calcification, dural tail sign, tumor level, tumor type, and tumor location between the S and M groups. Values are expressed as mean ± standard deviation (SD). Statistical significance was set at p < 0.05. To identify independent factors for distinguishing between schwannomas and meningiomas, multivariate logistic regression analysis was conducted. Independent variables with p-values <0.1 in the univariate analysis, including the SUVmax of FDG-PET, were eligible for inclusion in the multivariate models.

Results

SUVmax on FDG-PET in the S and M groups based on tumor type and spinal level

Although the SUVmax of the spinal canal type tumor at the level of the cervical vertebrae was significantly higher in the M group (4.6 ± 0.8) than that in the S group (2.7 ± 1.4) (p = 0.017), there were no significant differences between the groups in terms of SUVmax in the spinal canal type tumor at all vertebral levels (S group, 3.1 ± 1.1; M group, 3.5 ± 1.7) and at the thoracic level (S group, 3.5 ± 1.0, M group, 2.7 ± 1.6) (Table 1). There was a positive correlation between the SUVmax and tumor volume in the S group (r = 0.636, p < 0.01) (Figure 5). However, there were no correlations between the SUVmax and tumor volume in the M group (Figure 5).
| Spinal canal type | SUVmax | M group (n = 14) | p-value<sup>b</sup> |
|-------------------|--------|-----------------|--------------------|
| All<sup>a</sup> (n) | 3.1 ± 1.1 (15) | 3.3 ± 1.7 (14) | 0.270 |
| Cervical<sup>a</sup> (n) | 2.7 ± 1.4 (6) | 4.6 ± 0.8 (5) | 0.017* |
| Thoracic<sup>a</sup> (n) | 3.5 ± 1.0 (7) | 2.7 ± 1.6 (9) | 0.408 |
| Lumbar<sup>a</sup> (n) | 2.9 ± 0.5 (3) | - (0) | - |
| Dumbbell type | SUVmax | M group (n = 14) | |
| All<sup>a</sup> (n) | 5.1 ± 1.9 (13) | - (0) | - |
| Cervical<sup>a</sup> (n) | 4.9 ± 1.9 (6) | - (0) | - |
| Thoracic<sup>a</sup> (n) | 7.6 ± 3.0 (2) | - (0) | - |
| Lumbar<sup>a</sup> (n) | 4.4 ± 0.7 (5) | - (0) | - |

TABLE 1: SUVmax on FDG-PET in the S and M groups based on tumor type and spinal level.

<sup>a</sup>Mean ± SD.

<sup>b</sup>Significant differences (p < 0.05) between the S and M groups were calculated using the *Mann–Whitney U test.

SUVmax: maximum standardized uptake value; FDG-PET: 18F-fluorodeoxyglucose-positron emission tomography; S and M group: schwannomas and meningiomas group.
FIGURE 5: Relationship between SUVmax and tumor volume in the S and M groups.

(A) Schwannoma. ○: Dumbbell type, ●: Spinal canal type. (B) Meningioma.

●: Spinal canal type. Significant differences (p < 0.05) were calculated using the *Spearman’s rank correlation coefficient. The black circle indicates the spinal canal type. The white circle indicates the dumbbell type.

*SUVmax: maximum standardized uptake value.

Table 2 summarizes the univariate and multivariate predictors of the differential diagnosis between the S and M groups. The mean age of the M group was significantly higher than that of the S group (p = 0.017). There were no significant differences in sex, BMI, or duration of disease between the S and M groups. The prevalence of tumors at the level of the lumbar vertebrae was significantly higher in the S group than in the M group (p = 0.044), and the prevalence of tumors at the level of the thoracic vertebrae was significantly higher in the M group than in the S group (p = 0.047). However, there were no significant differences between the S and M groups in terms of the prevalence of tumors at the cervical level. In terms of the type of tumor, the prevalence of the spinal canal type was significantly higher in the M group (p < 0.001), while that of the dumbbell type was significantly higher in the S group (p < 0.001). Regarding tumor location, the prevalence of the ventral type was significantly higher in the M group (p < 0.001), while that of the dorsal type was significantly higher in the S group (p < 0.001). The prevalence of calcification was significantly higher in the M group than in the S group (p < 0.001). The tumor volume was significantly higher in the S group (11.5 ± 22.1 cm³) than in the M group (2.2 ± 0.9 cm³) (p = 0.004).
### TABLE 2: Univariate and multivariate predictors of differential diagnosis between S and M groups.

OR: odds ratio; BMI: body mass index; CI: confidence interval; SUVmax: maximum standardized uptake value.

| Variables                     | S group (n = 28) | M group (n = 14) | p-value<sup>b</sup> | OR      | 95% CI       | p-value<sup>c</sup> |
|-------------------------------|-----------------|-----------------|----------------------|---------|--------------|----------------------|
| Age<sup>a</sup> [years]       | 56.7 ± 15.1     | 67.9 ± 14.6     | 0.017*               | 0.080   | -0.001-10.006| 0.165                |
| Male sex [%] (n)              | 32.1 (9)        | 16.7 (2)        | 0.195                | 0.065   | -0.056-0.195 | 0.266                |
| BMI<sup>a</sup> [kg/m<sup>2</sup>] | 22.0 ± 4.0     | 22.9 ± 2.6      | 0.107                | 0.043   | -0.009-0.021 | 0.447                |
| Duration of disease<sup>a</sup> [months] | 11.8 ± 10.5   | 10.0 ± 7.0      | 0.842                | -       | -            | -                    |
| Cervical level of tumor [%] (n) | 71.4 (12)       | 35.7 (6)        | 0.747                | -       | -            | -                    |
| Spinal canal type of tumor [%] (n) | 46.4 (13)      | 0 (0)           | 0.002<sup>b</sup>   | 0.010   | -0.147-0.168 | 0.894                |
| Ventral location of tumor [%] (n) | 25.0 (7)        | 85.7 (12)       | <0.001<sup>b</sup>  | -0.095  | -0.231-0.051 | 0.204                |
| Calcification [%] (n)         | 0 (0)           | 42.9 (6)        | <0.001<sup>b</sup>  | -0.009  | -0.196-0.172 | 0.896                |
| Dural tail sign [%] (n)       | 0 (0)           | 92.9 (13)       | <0.001<sup>b</sup>  | 0.851   | 0.704-1.031  | <0.001<sup>b</sup>   |
| Tumor volume<sup>a</sup> [cm<sup>3</sup>] | 11.5 ± 22.1     | 2.2 ± 0.9       | 0.004*               | -0.009  | -0.004-0.003 | 0.894                |
| SUVmax                        | 4.1 ± 1.8       | 3.3 ± 1.7       | 0.743                | -0.42   | -0.048-0.026 | 0.538                |

Multivariate logistic regression analysis showed that the dural tail sign was significantly associated with differential diagnosis between the S and M groups (odds ratio [OR], 0.851; 95% CI, 0.704-1.031, p < 0.001).

### Discussion

To the best of our knowledge, this is the first study to investigate whether SUVmax on FDG-PET is useful for the differential diagnosis between schwannomas and meningiomas. Although the SUVmax of the spinal canal type tumor at the level of the cervical vertebrae was significantly higher in meningiomas than in schwannomas, the dural tail sign on MRI was the most useful for the differential diagnosis between schwannomas and meningiomas. This finding was similar to the results of previous reports.

Dural resection and reconstruction are required in cases of intradural meningiomas; therefore, it is crucial to distinguish between schwannomas and meningiomas before surgery [19]. In this study, both tumors were differentiated by intraoperative pathological examinations in all cases. However, this is not possible at all institutions. Therefore, the dural tail sign, and not FDG-PET, was the most useful finding for the differential diagnosis between schwannomas and meningiomas in this study.

In this study, the age of the M group was significantly higher than that of the S group. Previous studies have reported that schwannomas occur most frequently in patients in their thirties and forties [20-22], and meningiomas are most common in patients in their fifties, sixties, and seventies [19,23]; these findings are in concordance with the results of the present study. Previous studies have reported that meningiomas are more common in women [24,25]. In our study, although not significant, patients with meningiomas tended to have more complications than those with schwannomas.

The present study demonstrated that the prevalence of tumors at the level of the thoracic and lumbar vertebrae was significantly higher in the S group than in the M group. De Verdelhan et al. [4] reported that meningiomas are most common at the level of the thoracic vertebrae, but rarely occur at the level of the...
The present study demonstrated that in spinal canal-type tumors at the level of the cervical vertebrae, the SUVmax was significantly higher in the M group than in the S group. However, there were no significant differences between the groups in terms of SUVmax after correction of tumor volume in the spinal canal type at all vertebral levels, including the cervical and thoracic levels. Do et al. [27] described the pattern of 18F-FDG uptake in the spinal cord in 92 patients with non-central nervous system malignancies. They defined the cord-to-background ratio as the ratio of the SUVmax of the entire spinal cord to that of the LS levels; they found that the mean ratio decreased at each spinal level in a craniocaudal direction. In this study, the SUVmax of spinal cord tumors did not decrease at any spinal level in the craniocaudal direction. Tomura et al. [28] found that in cases of ependymoma, the SUVmax with 11C-Metionine (MET) and FDG was 2.2 to 3.5 and 3.5 to 11.2, respectively. Matsumoto et al. [29] reported that the mean SUVmax of the primary malignant spine/spinal tumors was 8.4 ± 6.2. In this study, the SUVmax of spinal schwannomas and meningiomas was higher than that of the normal spinal cord and lower than that of malignant spinal cord tumors. Therefore, in cases of malignant spinal cord tumors, including metastases from cancer, the SUVmax that we found may be considered a reference value. Moreover, we demonstrated a positive correlation between SUVmax and tumor volume in the S group. This may be because the tumor volume of the dumbbell type in the S group was larger than that in the spinal canal type. Although our findings suggest that SUVmax is not useful for the differential diagnosis of these tumors compared with CT and MRI, the evaluation of schwannomas using PET/CT needs tumor size correction because schwannomas are variable in their size. Based on the results of this study, performing PET/CT in all cases due to radiation exposure is not recommended. However, it may be useful for differentiating between tumors in patients with a history of malignant disease or metastasis [17]. It has been reported that the average SUVmax of the metastatic spinal tumors was 6.7, but in this study, the average SUVmax values of the S and M groups were 4.1 and 3.3, respectively. Therefore, the SUVmax on FDG-PET in this study varied when compared with that of malignant tumors.

This study had certain limitations. First, we only included World Health Organization grade I tumors; grade II or III tumors were not included because the number of cases was small. A previous study reported the utility of 18F-FDG-PET in the assessment of tumor grade in intracranial meningiomas [30], including histological grades and types, which may further improve the preoperative diagnosis of these tumors. Second, previous studies considered the pathology and MIB-1 index [28,30], but these parameters were not evaluated in this study. Third, since the number of cases was small, no clear cutoff value of the SUVmax was found in the spinal canal-type tumors at the level of the cervical vertebrae, which would distinguish spinal schwannomas from meningiomas. Fourth, despite a relatively small sample size, the standard deviation of SUVmax values at each level in the spinal canal type was small in this study. In the future, well-designed large-scale studies will be needed to further explore the association between SUVmax and spinal cord tumors. Fifth, we cannot reveal a precise mechanism to state that the SUVmax of the spinal canal type tumor at the level of the cervical vertebrae was significantly higher in the M group than that in the S group. Although there were several limitations, future studies, including larger samples, histological grades and types, and molecular characteristics, may further improve the preoperative diagnosis of these tumors.

Conclusions

We investigated whether SUVmax on FDG-PET is useful for the differential diagnosis between schwannomas and meningiomas. Although the SUVmax of the spinal canal type tumors at the level of the cervical vertebrae was significantly higher in meningiomas than in schwannomas, the dural tail sign on CT and MRI was the most useful for the differential diagnosis between schwannomas and meningiomas.

Additional Information

Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study. The ethics committee of Hirosaki University Graduate School of Medicine issued approval 2019-1038. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an
interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

This study was supported by Dr Toshihiro Tanaka from the Department of Orthopaedics, Takaoka Seishikai Hospital, Toyama, Japan, Dr Kenji Kowatari from the Department of Orthopaedics, Tsgurag General Hospital, Aomori, Japan and Dr Hitoshi Kudo from the Department of Orthopaedics, Japan Community Health care Organization Akita Hospital, Akita, Japan.

References

1. BU JW: Spinal menigomas and neurofibromas. Acta Radiol. 1953, 40:283-500. 10.3109/0001692530176591
2. Iraci G, Peserico L, Salar G: Intraspinal neurinomas and menigomas. A clinical survey of 172 cases . Int Surg. 1971, 56:289-305.
3. Levy WJ, Latchaw J, Hahn JF, Sawhney B, Bay J, Dohn DF: Spinal neurofibromas: a report of 66 cases and a comparison with meninomas. Neurosurgery. 1986, 18:331-4. 10.1093/00016123-198605000-00013
4. De Verdellhan O, Haregen C, Carsin-Nicol B, et al.: MR imaging features of spinal schwannomas and menigomas. J Neuroladiol. 2005, 32:42-5. 10.1016/S0041-3702(05)50502-1
5. Goldshein D, Litt AW, Pinto RS, Bannon KR, Krich KF: Dural ‘tail’ associated with meningomas on Gd-DTPA-enhanced MR images: characteristics, differential diagnostic value, and possible implications for treatment. Radiology. 1990, 176:447-50. 10.1148/radiology.176.2.2367659
6. Sotoudeh H, Yazdi HR: A review on dural tail sign. World J Radiol. 2010, 2:188-92. 10.4529/wjr.v2.i5.188
7. Takemoto K, Matsumura Y, Hashimoto H, et al.: MR imaging of intraspinal tumors—capability in histological differentiation and compartmentalization of extramedullary tumors. Neuroradiology. 1988, 30:503-9. 10.1007/BF00328180
8. Albanese V, Platania N: Spinal extradural extramedullary tumors. Personal experience . J Neurosci. 2002, 46:18-24.
9. McCormick PC: Anatomic principles of intradural spinal surgery. Cilt Neurosurg. 1994, 41:204-25.
10. Mihaillidou D: Nuclear Medicine Physics: The Basics. 7th ed . Med Phys. 2012, 39:625. 10.1118/1.4752082
11. Alavi A, Jung JW, Zhang H: Implications of PET based molecular imaging on the current and future practice of medicine. Semin Nucl Med. 2004, 34:56-69. 10.1053/j.snumed.2003.09.007
12. Even-Sapir E: PET/CT in malignant bone disease . Semin Musculoskelet Radiol. 2007, 11:512-21. 10.1055/s-2008-1060354
13. Townsend DW, Beyer T, Blodgett TM: PET/CT scanners: a hardware approach to image fusion . Semin Nucl Med. 2005, 35:195-204. 10.1053/anuc.2005.127314
14. Kubota K, Ito K, Morooka M, et al.: FDG PET for rheumatoid arthritis: basic considerations and whole-body PET/CT. Ann N Y Acad Sci. 2011, 1228:29-58. 10.1111/j.1749-6633.2011.06518.x
15. Liu Y: Orthopedic surgery-related benign uptake on FDG-PET: case examples and pitfalls . Ann Nucl Med. 2009, 23:701-8. 10.1007/s12149-009-0296-7
16. Shin DS, Shon OJ, Han DS, Choi HH, Chun KA, Cho IH: The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors. Ann Nucl Med. 2008, 22:605-9. 10.1016/j.ajnr.a.00151-2
17. Mostardi PM, Diefenb FE, Rykken J, et al.: Intramedullary spinal cord metastases: visibility on PET and correlation with MRI features. AJNR Am J Neuroradiol. 2014, 35:196-201. 10.3174/jnr.2013.A3618
18. Ichikawa N, Kumagai G, Wada K, et al.: Coagulation, vascular morphology, and vasculogenesis in spinal ligament ossification model mice. Spine. 2021, 46:E802-9. 10.1097/BR.0000000000005891
19. Gottfried ON, Gulf W, Quinones-Hinojosa A, Kan P, Schmidt MH: Spinal menigomas: surgical management and outcome. Neurorsurg Focus. 2005, 14:e2. 10.3171/2005.4.00E2
20. Celli P, Trillò G, Ferrante L: Spinal extradural schwannoma. J Neurosurg Spine. 2005, 2:447-56. 10.1097/000169255-2005.2.00447
21. Conti P, Pansini G, Mouchaty H, Capuano C, Conti R: Spinal neurinomas: retrospective analysis and long-term outcome of 179 consecutively operated cases and review of the literature. Surg Neurol. 2004, 61:34-43. 10.1007/s10090-004-0051-7
22. Klempaj J, Simmii M: Surgery of spinal nerve sheath tumors with special reference to neurofibromatosis . Neurosurgery. 1998, 42:279-89. 10.1097/00006123-199802000-00004
23. Solero CL, Fornari G, Milombi S, Lasio G, Oliveri G, Cimino C, Pluchino F: Spinal menigomas: review of 174 operated cases. Neurosurgery. 1989, 25:153-60. 10.1093/00016123-198908000-00001
24. Cohen-Gadol AA, Zikel OM, Koch CA, Scheithauer BW, Krauss WE: Spinal menigomas in patients younger than 50 years of age: a 21-year experience. J Neuurosurg. 2003, 98:258-63. 10.3171/2003.9.25858
25. Roux FX, Natal F, Pinaudeau M, Borne G, Devaux B, Meder JF: Intraspinial menigomas: review of 54 cases with discussion of poor prognostic factors and modern therapeutic management. Surg Neurol. 1996, 46:458-64. 10.1016/0039-9755(96)00199-1
26. Osawa H, Kokubu H, Asaiwa T, Hoshikawa T, Sawa M: Spinal dumbbell tumors: an analysis of a series of 118 cases . J Neurosurp Spine. 2007, 7:587-93. 10.3171/SP.07/12.587
27. Do BH, Mari C, Tieng JF, Quon A, Rosenberg J, Biswal S: Pattern of 18F-FDG uptake in the spinal cord in patients with non-central nervous system malignancy. Spine. 2011, 36:E159-401. 10.1097/BRS.0b013e31820a7d4b
28. Tomura N, Ito Y, Matsuoka H, Sagiynoya T, Namazawa SI, Mizuno Y, Watanabe K: PET findings of intramedullary tumors of the spinal cord using [18F]FDG and [11C]methionine. AJNR Am J Neuroradiol. 2013, 34:1278-83. 10.3174/jnr.A3534
29. Matsuomo Y, Baba S, Endo M, et al.: Metabolic tumor volume by 18F-FDG PET/CT can predict the clinical outcome of primary malignant spine/spinal tumors. Biomed Res Int. 2017, 2017:8152676.
30. Lee JW, Kang KW, Park SH, et al.: 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging. 2009, 36:1574-82. 10.1007/s00259-009-1133-x